Mar. 2 at 9:54 PM
$ARQT For a comparison, AAOI just reported revenue for Q4 of
$134.3 million up 34% YoY with a loss of $.01 per share. The stock price soared from
$40 pps to
$102.51 in 2 days of trading. All the analysts raised their price targets to
$100+ pps. While the Revenue forecasts are showing only 30%+ growth.
Different industry, but it still provides a stark contrast to the
$4+ per share loss following ARQT’s stunning 82% revenue growth YoY and $.13 per share profit, both of which significantly exceeded expectations.
The analyst’s maintaining their paltry price target’s at
$30+ DESPITE the stunning growth & earnings beat is probably a factor in the price action.
Look for a big pharma Buy Out offer, which will explain why all of this manipulative & coordinated price suppression makes no sense.
